Truist Securities Maintains Buy on Axogen, Lowers Price Target to $53

Benzinga Newsdesk www.benzinga.com Negative 52.1%

Neg 52.1% Neu 0% Pos 0%

Truist Securities analyst Ravi Misra maintains Axogen (NASDAQ:AXGN) with a Buy and lowers the price target from $60 to $53.